Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...
The shares had a strong run in 2024, but 2025 doesn’t look as promising, according to Citizen JMP Securities analyst Andrew ...